FDA FIELD FORCE MANAGEMENT
This article was originally published in The Gold Sheet
Executive Summary
...is searching for ways to enhance the productivity of resources stretched thin by an expanding workload. The Team Biologics program is unfolding on schedule, meeting field management’s target of inspecting at least 50% of the team’s inventory, which now includes therapeutic biologics, in FY ‘99. Experience is being gained in the drug area on a handful of initiatives originally applied to medical devices including investigator certification, pre-announced inspections and annotated 483s. The inspection MRA with the EU is moving into the second year of a "transition" phase with key pieces of the puzzle not yet in place including the completion of a harmonized bulk drug GMP guideline, currently being developed through the ICH process.
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.